Beyond study cohorts: Visualizing patient experience informed by patient-reported outcomes (PROs) deployed in multiple myeloma clinical practice.

e23207 Background: Integrating PROs into oncology care has been proven to enhance patient outcomes and reduce health resource utilization. While PRO trends can be assessed through large cohort studies, day-to-day care may warrant clinician comparison of patterns in small subsets of individual patient records. We introduce here an approach to rapidly visualize trends of high-risk multiple myeloma (MM) PROs from a real-world digital care platform. Methods: Eligible patients with high-risk MM were enrolled in PROmpt (an ePRO platform) from 9/2020 to 11/2024 and received Induction (I/C) or Maintenance (M) treatment. High-risk criteria were RISS stage III, “high-risk cytogenetics presence” indicator, t(14;16), t(4;14), del(17p), TP53+, or 1q gain. Heat maps were generated to illustrate patterns of symptom (SX) reports, PRO-CTCAE consensus score, treatment bother (TB) using FACT-GP5, quality-of-life (QoL), and function from each patient for &gt; / =12 weeks. Results: Twenty-two MM patients were included with 8 (36.3%) in the I/C and 14 (63.7%) in the M group. Patients were aged 46-87, 11 males and 18 White. Five I/C patients received Dara VRd, 2 KRd, and 1 DRD. Ten M patients received doublets or triplets, with the rest on monotherapy. Five I/C patients on Dara VRd are summarized in Table 1. While the heatmaps showed weekly reports, the table was aggregated in 4-week intervals with SX counts, GP5, pain, and peripheral neuropathy (PN) scores. In T1 (weeks 1-4), patients had median 2 SXs (range = 0.5-3) and median GP5 1.5 (range = 1-2.5). Patient(P)1 reported high TB across time periods, likely induced by moderate PN and SX counts. P2 reported low TB in T1 and T2 (weeks 5-8) but increasing in T3 (weeks 9-12+) as pain and PN escalated in severity. P3 reported relatively low TB, likely due to fewer SX experienced but severe pain was reported in T2. P4 experienced several SXs, moderate pain and mild PN in T1 yet was better managed over time. P5 reported moderate TB despite fewer SXs and mild pain/PN, potentially related to frailty level. Conclusions: In-depth exploration showed unique patient experiences in MM patients on Dara VRd I/C by longitudinal SX burden and TB, indicating a vital role for PRO-informed tailoring of care management. Embedded digital PRO platforms paired with heat map visualization can empower clinicians to efficiently review granular results across small patient cohorts and efficiently incorporate assessments into clinical care. Aggregated PROs of I/C Patients on Dara VRd. Patient Frailty T1 T2 T3 Sx # GP5 Pain PN Sx # GP5 Pain PN Sx # GP5 Pain PN 1 Fit 3 2.5 0 2 2 2.5 0 1 3.5 3 0.5 1.5 2 Fit 2 1 0 0 3.5 1 0.5 0.5 4 3 2 2 3 Fit 1 1 1.5 0 1.5 1.5 3 0 1.5 1 2 0 4 Frail 3 1.5 1.5 0.5 4 1 1 0.5 2.5 0.5 1 0 5 Frail 0.5 2 0 0 1.5 2 0 0 1.5 2 0 0.5 Sx #: No. of SX. Higher score indicates higher TB (GP5) or severity (Pain/PN). </jats:t